Antidepressant Selection for Elderly Patients with Cardiovascular Disease

Rationale for Selecting Sertraline

• The American Heart Association recommends sertraline as a preferred antidepressant for patients with cardiovascular disease due to its lower risk of QTc prolongation compared to other SSRIs 1, 2
• Sertraline has been extensively studied in patients with coronary heart disease and heart failure, demonstrating a lower risk of QTc prolongation than citalopram or escitalopram, making it a safer choice for patients with extensive cardiac history 1, 2
• The European Society of Cardiology Working Group advises against using medications like mirtazapine that may precipitate or exacerbate orthostatic hypotension in elderly patients, supporting the selection of sertraline 4

Cardiovascular Safety and Hyponatremia Considerations

• Monoamine oxidase inhibitors and tricyclic antidepressants should be avoided in patients with cardiovascular disease due to significant cardiovascular side effects, including hypertension, hypotension, and arrhythmias 1, 2, 3
• Mirtazapine poses a significant risk of orthostatic hypotension in elderly patients, particularly those with cardiovascular disease and a history of falls, making sertraline a preferable option 4

Monitoring and Implementation

• The American College of Cardiology recommends monitoring serum sodium levels and blood pressure in patients initiated on sertraline, especially in those with cardiovascular disease and baseline borderline-low sodium 1, 2
• Patients on sertraline should be monitored for QTc prolongation if they are on other QT-prolonging medications or have baseline cardiac conduction abnormalities 3